Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates
- PMID: 25481037
- DOI: 10.1016/j.juro.2014.11.096
Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates
Abstract
Purpose: We determined if the USPSTF recommendation against prostate specific antigen screening was associated with a change in biopsy and cancer detection rates.
Materials and methods: We conducted a time series analysis (October 2008 to June 2013) of prostate biopsies performed at University Health Network (Toronto). Biopsies for active surveillance or solely targeting magnetic resonance imaging detected lesions were excluded from study. Interventional ARIMA models with step functions were used to examine changes in the number of biopsies performed and cancers detected per month. Low risk prostate cancer was defined as no Gleason pattern 4 or greater, 3 or fewer cores involved, or 1/3 or less of the total number of cores involved, and no core with greater than 50% cancer involvement. Intermediate to high grade prostate cancer was defined as Gleason 7-10.
Results: A total of 3,408 biopsies were performed and 1,601 (47.0%) prostate cancers were detected (low risk prostate cancer 563 [16.5%], intermediate to high grade prostate cancer 914 [26.8%]). The median number of biopsies per month decreased from 58.0 (IQR 54.5-63.0) before the recommendations to 35.5 (IQR 27.0-41.0) afterward (p=0.003), while the median number of patients undergoing first-time biopsy decreased from 42.5 (IQR 37.5-45.5) to 24.0 (IQR 19.0-32.5, p=0.025). The median number of low risk prostate cancers detected per month decreased from 8.5 (IQR 6.5-10.5) to 5.5 (IQR 4.0-7.0, p=0.012), while the median number of intermediate to high grade prostate cancers per month decreased from 17.5 (IQR 14.5-21.5) to 10.0 (IQR 9.0-12.0, p <0.001).
Conclusions: After the USPSTF recommendation the number of biopsies performed (total and first-time), based on referrals from our catchment area, has decreased. This is likely due to decreased use of prostate specific antigen screening. Although it is encouraging that fewer low risk prostate cancers are being diagnosed, the sudden decrease in the detection rate of Gleason 7-10 prostate cancers is concerning.
Keywords: biopsy; early detection of cancer; prostate; prostatic neoplasms.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.Investig Clin Urol. 2017 Nov;58(6):423-428. doi: 10.4111/icu.2017.58.6.423. Epub 2017 Nov 2. Investig Clin Urol. 2017. PMID: 29124241 Free PMC article.
-
Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.J Urol. 2016 Jan;195(1):66-73. doi: 10.1016/j.juro.2015.07.099. Epub 2015 Aug 6. J Urol. 2016. PMID: 26254722
-
Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.J Urol. 2015 Dec;194(6):1587-93. doi: 10.1016/j.juro.2015.06.075. Epub 2015 Jun 15. J Urol. 2015. PMID: 26087383
-
Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.ANZ J Surg. 2018 Jul-Aug;88(7-8):E589-E593. doi: 10.1111/ans.14275. Epub 2017 Nov 30. ANZ J Surg. 2018. PMID: 29194902 Review.
-
Recent Changes in Prostate Cancer Screening Practices and Epidemiology.J Urol. 2017 Dec;198(6):1230-1240. doi: 10.1016/j.juro.2017.05.074. Epub 2017 May 25. J Urol. 2017. PMID: 28552708 Review.
Cited by
-
UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.Can Urol Assoc J. 2022 Apr;16(4):E184-E196. doi: 10.5489/cuaj.7851. Can Urol Assoc J. 2022. PMID: 35358414 Free PMC article. No abstract available.
-
Transrectal ultrasound guided prostate biopsy performed by supervised junior and senior residents is safe and does not result in inferior outcomes.Am J Clin Exp Urol. 2021 Feb 15;9(1):150-156. eCollection 2021. Am J Clin Exp Urol. 2021. PMID: 33816703 Free PMC article.
-
Prostate Cancer Screening in Brazil: a single center experience in the public health system.Int Braz J Urol. 2021 May-Jun;47(3):558-565. doi: 10.1590/S1677-5538.IBJU.2020.0392. Int Braz J Urol. 2021. PMID: 33621004 Free PMC article.
-
Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study.BMC Urol. 2021 Feb 8;21(1):20. doi: 10.1186/s12894-021-00784-w. BMC Urol. 2021. PMID: 33557801 Free PMC article.
-
Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice.J Gen Intern Med. 2020 May;35(5):1368-1374. doi: 10.1007/s11606-019-05561-y. Epub 2019 Dec 9. J Gen Intern Med. 2020. PMID: 31820217 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
